



IBA – DATA CONCERNING TRANSPARENCY

Louvain-la-Neuve, Belgium, January 20, 2014 - IBA (Ion Beam Applications SA, EURONEXT), the world's leading provider of proton therapy solutions for the treatment of cancer, today announces, in accordance with Article 29 §1 al.2 of the Transparency Law (law of May 2, 2007 and Royal Decree of February 14, 2008), that IBA has issued 2 transparency notifications today, the content of which is summarized below.

- The agreement on the holding, acquisition or sale of shares with voting rights entered into between Belgian Anchorage SCRL, UCL ASBL, Sopartec SA and IRE on February 6, 1996 was terminated with effect as from December 2, 2013, therefore bringing the holding of the said parties below the 35% threshold. The notification could not be made earlier further to pending negotiations regarding reconduction of the said agreement.

ENTITY	NUMBER OF SHARES WITH VOTING RIGHTS AS AT 5 NOV. 2008 (LAST TRANSPARENCY NOTIFICATION)	NUMBER OF SHARES WITH VOTING RIGHTS AS AT 9 JANUARY 2014	% OF SHARES WITH VOTING RIGHTS AS AT 9 JANUARY 2014 (DENOMINATOR = 27 635 439)
a. Belgian Anchorage SCRL (BA) Clos des Salanganes 5 1150 Bruxelles	7 773 132	7 700 132	27.86%
b. IBA SA Chemin du Cyclotron 3 1348 Louvain-la-Neuve Not a party to the Agreement but affiliated with BA	0	75 637	0.27%
c. IBA Investments SCRL Chemin du Cyclotron 3 1348 Louvain-la-Neuve Not a party to the Agreement but affiliated with BA	393 692	610 852	2.21%
Sub total a, b, c	8 166 824	8 386 621	30.35%
d. UCL ASBL Place de l'Université 1 1348 Louvain-la-Neuve	426 885		
e. Sopartec SA Place de l'Université 1 1348 Louvain-la-Neuve	529 925		
f. Institut des Radioéléments FUP Zoning Industriel, Avenue de l'Espérance 1 6220 Fleurus	1 423 271	1 423 271	5.15%



2. On January 10, 2014, Belgian Anchorage SCRL sold 140 000 shares with voting rights, therefore bringing the holding of Belgian Anchorage SCRL and its affiliates IBA SA and IBA Investments SCRL below the 30% threshold.

ENTITY	NUMBER OF SHARES WITH VOTING RIGHTS AS AT 9 JANUARY 2014	NUMBER OF SHARES WITH VOTING RIGHTS AS AT 20 JANUARY 2014	% OF SHARES WITH VOTING RIGHTS AS AT 20 JANUARY 2014 (DENOMINATOR = 27 635 439)
a. Belgian Anchorage SCRL (BA) Clos des Salanganes 5 1150 Bruxelles	7 700 132	7 560 132	27.36%
b. IBA SA Chemin du Cyclotron 3 1348 Louvain-la-Neuve	75 637	75 637	0.27%
c. IBA Investments SCRL Chemin du Cyclotron 3 1348 Louvain-la-Neuve	610 852	610 852	2.21%
Sub total a, b, c	8 386 621	8 246 621	29.84%

* * *
*

About IBA

IBA (Ion Beam Applications SA) is a cancer diagnostics and treatment equipment company, and the worldwide technology leader in the field of proton therapy, the most advanced form of radiotherapy available today.

The Company’s primary expertise lies in the development of next generation proton therapy technologies that provide oncology care providers with premium quality services and equipment. IBA’s proton therapy solutions are scalable and adaptable, offering universal full scale proton therapy centers as well as next generation compact, single room solutions. IBA also focuses on the development and supply of dosimetry solutions for Quality Assurance of medical equipment and increased patient safety as well as particle accelerators for medical and industrial applications.

IBA employs more than 1,000 people worldwide and is listed on Euronext Brussels, (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB), more information can be found at: www.iba-worldwide.com

Press release |

Regulated information



For more information, please contact

IBA

Jean-Marc Bothy

Chief Financial Officer

Tel: +32 10 47 58 90

investorrelations@iba-group.com

Thomas Ralet

Vice-President Corporate Communication

Tel : +32 10 47 58 90

communication@iba-group.com